The Central and Eastern Europe (CEE) life sciences sector is emerging as a significant hub for investment and growth, driven by its growing GDP per capita, skilled workforce, and regulatory alignment with the EU. From 2010 to 2024, the region’s GDP per capita rose from 41.8% to 62.4% of the European average, with life sciences playing a significant role in this economic development. Poland and Hungary are leading the region, while other countries like Romania and Serbia are showing promising growth in scientific vacancies.
Poland has positioned itself as the frontrunner in the region, accounting for 32% of all CEE life sciences vacancies. Its strong clinical trial infrastructure, skilled labour, and innovative R&D hubs like the BioTechMed Mazovia Cluster are key drivers. Biotech vacancies in Poland are set to grow by 93.5%, though contract research organisations (CROs) are seeing declining demand due to the rise of AI automation. Meanwhile, the pharmaceutical sector remains dominant, supported by leading firms such as GSK, Pfizer, and Novartis.
Hungary, the second-largest player, accounts for 19.8% of regional life sciences vacancies. While vacancies are expected to decline by 13.2% in 2025 after a surge in hiring in 2024, the sector remains robust. Pharmaceutical firms and CROs specialising in early-phase trials are key contributors to Hungary’s success, backed by EU funds and a strong talent pipeline. Additionally, biotech startups are thriving with the help of science parks and innovation funding.
Overall, the CEE region presents unique opportunities for life sciences growth, thanks to its competitive cost base, regulatory progress, and expanding infrastructure. However, challenges like limited domestic venture capital and modernisation needs in non-EU countries remain. Success will depend on bold reforms and a willingness to scale, as the sector races to capitalise on this critical moment for investment and innovation.